Literature DB >> 28060105

Myofibroma in Infancy and Childhood.

Priya Mahajan1, John Hicks, Murali Chintagumpala, Rajkumar Venkatramani.   

Abstract

Myofibromas are rare fibroblastic-myofibroblastic tumors in children. Their biological behavior is unpredictable and spontaneous regressions have been described. This is a retrospective review of clinical characteristics, treatment, and outcome of children diagnosed with myofibroma between 1999 and 2013 at Texas Children's Hospital. The median age at diagnosis of 42 patients was 37 months. Approximately two thirds of the patients were male. The median length of follow-up was 50.5 months (range, 0 to 165 mo). Thirty-eight patients (90%) had solitary lesions; 19 (50%) in the head and neck, 10 (26%) in the limbs, and 9 (24%) in the trunk. Twelve patients underwent a complete surgical resection. Of the 30 patients with positive margins, only 1 had tumor progression. Two patients had multicentric involvement, and 2 patients had generalized disease with visceral involvement. One patient with generalized disease and a progressive maxillary sinus mass was treated with vinblastine and methotrexate chemotherapy followed by complete surgical resection. All patients were alive at last follow-up. Myofibromas of childhood demonstrate clinical variability, and may spontaneously regress. Positive surgical margins do not adversely affect outcome. The rare patient with progressive unresectable disease may benefit from chemotherapy.

Entities:  

Mesh:

Year:  2017        PMID: 28060105     DOI: 10.1097/MPH.0000000000000732

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Primary paediatric chest wall tumours necessitating surgical management.

Authors:  N Maistry; J Durell; S Wilson; K Lakhoo
Journal:  Ann R Coll Surg Engl       Date:  2020-03-11       Impact factor: 1.891

2.  Solitary orbital myofibroma in a child: A rare case report with literature review.

Authors:  Bejjanki Kavya Madhuri; Devjyoti Tripathy; Ruchi Mittal
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.